Hartman G D, Duggan M E
Department of Medicinal Chemistry, Merck Research Laboratories, WP14-2, West Point, PA 19486, USA.
Expert Opin Investig Drugs. 2000 Jun;9(6):1281-91. doi: 10.1517/13543784.9.6.1281.
The alpha(v)beta(3) integrin is a non-covalent, heterodimeric, cell-surface protein that is expressed with varying density on numerous cell types, including osteoclasts, vascular smooth muscle cells, endothelial cells and a variety of tumour cells. Functionally, alpha(v)beta(3) mediates a diverse range of biological events including the adhesion of osteoclasts to bone matrix, smooth muscle cell migration and angiogenesis. Specifically, there has been significant attention focused on the preparation of inhibitors of alpha(v)beta(3) for use as inhibitors of bone resorption, in recognition of the medical need for improved prevention and treatment of osteoporosis. Herein, we summarise the pertinent chemistry and biological advances in the medicinal design and biological evaluation of peptide and small molecule alpha(v)beta(3) antagonists as inhibitors of bone resorption.
α(v)β(3)整合素是一种非共价的异二聚体细胞表面蛋白,在多种细胞类型中以不同密度表达,包括破骨细胞、血管平滑肌细胞、内皮细胞和多种肿瘤细胞。在功能上,α(v)β(3)介导多种生物学事件,包括破骨细胞与骨基质的黏附、平滑肌细胞迁移和血管生成。具体而言,鉴于对改善骨质疏松症预防和治疗的医学需求,人们对制备α(v)β(3)抑制剂作为骨吸收抑制剂给予了极大关注。在此,我们总结了肽类和小分子α(v)β(3)拮抗剂作为骨吸收抑制剂的药物设计和生物学评价中的相关化学和生物学进展。